ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Eprosartan
Drug: Eprosartan Mesylate
Drug: Placebo Eprosartan mesylate
Drug: Placebo Eprosartan

First Posted Date: 2012-06-29

Last Posted Date: 2014-07-25

Lead Sponsor: Abbott

Target Recruit Count: 665

Registration Number: NCT01631227

Locations: 🇩🇪
Site Reference ID/Investigator# 74066, Bochum, Germany
🇩🇪
Site Reference ID/Investigator# 74065, Dresden, Germany
🇩🇪
Site Reference ID/Investigator# 74062, Berlin, Germany

and more 35 locations

A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan

Completed

Conditions: Hypertension
Stroke

First Posted Date: 2012-03-26

Last Posted Date: 2014-08-12

Lead Sponsor: Abbott

Target Recruit Count: 533

Registration Number: NCT01562613

Locations: 🇬🇷
Site Reference ID/Investigator# 62508, Chania, Greece
🇬🇷
Site Reference ID/Investigator# 62511, Chania, Greece
🇬🇷
Site Reference ID/Investigator# 62487, Kalamata, Greece

and more 81 locations

A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: SLV354

First Posted Date: 2012-03-06

Last Posted Date: 2012-09-18

Lead Sponsor: Abbott

Target Recruit Count: 18

Registration Number: NCT01545310

Locations: 🇺🇸
Site Reference ID/Investigator# 52162, New Haven, Connecticut, United States

Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study

Completed

Conditions: Irregular Menstrual Cycle

First Posted Date: 2012-02-03

Last Posted Date: 2014-12-29

Lead Sponsor: Abbott

Target Recruit Count: 1000

Registration Number: NCT01525563

Locations: 🇮🇳
Site Reference ID/Investigator# 69506, Mumbai, India
🇮🇳
Site Reference ID/Investigator# 69009, Pune, India
🇮🇳
Site Reference ID/Investigator# 69010, Pune, India

and more 29 locations

A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: linifanib

First Posted Date: 2012-01-10

Last Posted Date: 2012-08-28

Lead Sponsor: Abbott

Target Recruit Count: 14

Registration Number: NCT01506934

Locations: 🇺🇸
Site Reference ID/Investigator# 61282, Detroit, Michigan, United States
🇺🇸
Site Reference ID/Investigator# 52122, San Antonio, Texas, United States
🇺🇸
Site Reference ID/Investigator# 51463, Lebanon, New Hampshire, United States

and more 1 locations

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-126
Drug: Placebo

First Posted Date: 2011-12-01

Last Posted Date: 2012-05-02

Lead Sponsor: Abbott

Target Recruit Count: 20

Registration Number: NCT01482845

Locations: 🇺🇸
Site Reference ID/Investigator# 62904, Hallandale Beach, Florida, United States
🇺🇸
Site Reference ID/Investigator# 62903, Orlando, Florida, United States
🇺🇸
Site Reference ID/Investigator# 62908, Glendale, California, United States

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

Phase 1

Completed

Conditions: Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine

Interventions: Drug: ABT-614
Drug: Placebo Comparator

First Posted Date: 2011-11-03

Last Posted Date: 2012-08-22

Lead Sponsor: Abbott

Target Recruit Count: 16

Registration Number: NCT01464320

Locations: 🇺🇸
Site Reference ID/Investigator# 63442, Miami, Florida, United States

A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic

Phase 4

Completed

Conditions: Cardiovascular Diseases
Dyslipidemias
Hypertriglyceridemia

Interventions: Drug: fenofibrate

First Posted Date: 2011-11-01

Last Posted Date: 2015-03-17

Lead Sponsor: Abbott

Target Recruit Count: 506

Registration Number: NCT01462877

Locations: 🇨🇳
Site Reference ID/Investigator# 64695, Xiamen, China

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Linifanib
Drug: Rifampin

First Posted Date: 2011-07-26

Last Posted Date: 2011-11-02

Lead Sponsor: Abbott

Target Recruit Count: 14

Registration Number: NCT01401933

Locations: 🇺🇸
Site Reference ID/Investigator# 49952, Madison, Wisconsin, United States
🇺🇸
Site Reference ID/Investigator# 49953, Tucson, Arizona, United States

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: linifanib

First Posted Date: 2011-06-27

Last Posted Date: 2012-03-23

Lead Sponsor: Abbott

Target Recruit Count: 13

Registration Number: NCT01381341

Locations: 🇺🇸
Site Reference ID/Investigator# 51403, Tacoma, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy